International Clinical Trials |
 |
|
|
|
|
 |
| |
|
|
|
|
The Digital Race for Early Detection and a Cure
Ijah Mondesire-Crump and Rahul Mahajan at nQ Medical
The urgent need for disease-modifying therapies will require further adoption of data-driven digital solutions for acceleration of development timelines with powerful, more efficient clinical trial designs
|
|
|
|
Developing the Optimal Recruitment Strategy
Gabbie St. Remy at CSSi
There are many factors that can lead to challenges in recruitment, and often trials struggle to meet enrolment milestones on time or on budget, so how can recruitment strategies be optimised to maximise enrolment?
|
|
|
|
|
Resilience and Risk: Breaking Ground in Oncology
ICT sits down with Andreas Voss at Swiss Rockets Ltd to discuss the oncological landscape, where he sees research heading, and ways in which the industry needs to grow to improve treatment options available to patients
|
|
|
|
Bringing the Trial to the Patient by Leveraging Electronic Technology
Karen A Gammon and Nikki Luttrell at Linical
Decentralised ‘virtual’ clinical trials in oncology are becoming the 'new normal' with the help of technology, but patient-centricity needs to remain the focus in this changing climate
|
|
|
|
Regulatory Challenges in Global CAR T Cell Therapy Development
Dr Brian Marks BSc, DC, and Ashley Jones MSc at Premier Research
When exploring the complex and rigorous regulatory landscape for CAR T cell therapies, sponsors may encounter challenges in their efforts to bring products to market
|
|
|
|
Surviving Isn’t Thriving
Jacqui Whiteway and Missy Hansen at PRA Health Sciences
With difficulties in research for paediatric cancer treatments, the RACE for Children Act brings hope for curing childhood cancer, and saving the lives of our most vulnerable members of society
|
|
|
|
|
Improving the Chances of EU Approval
Lisa Pascoe and Lucy Gluyas at PharmaLex
Managing regulatory approvals can be daunting, but taking steps to ensure success with early-stage input from regulatory teams inevitably builds a solid relationship with the competent authority assessors
|
|
|
|
The Impact of the EU MDR on Medical Device Supply Chains
Chad Reynolds at Maetrics
The new EU MDR deadline has been postponed to 2021, giving pharmaceutical and medical device companies extra time to get prepared for the many changes they will have to instigate
|
|
|
|
Speeding Clinical Trial Processes Through Greater Agility
Romuald Braun at Amplexor
Clinical trials are under the spotlight as the healthcare sector seeks to introduce innovative treatment as quickly as possible in the current health crisis. IT teams and suppliers can help companies to be more agile and responsive to changing market conditions
|
|
|
|
Exploring Common Questions for Your EU Drug Product Launch
Brian Lavery at Almac Group
With changing regulations and complex requirements, there are a number of regulatory submission strategy considerations that must be accounted for when launching a product in the EU
|
|
|
|
|
|
Preserving Trial Integrity During a Pandemic
Karen Ooms at Quanticate
In the face of COVID-19, clinical trials have a greater need for flexibility, but they still shouldn’t affect patients’ safety or compromise study validity
|
|
|
|
Integrated IT Systems and the Challenge of Globalisation
Lars Behrend and Michael Sigmund at SSS International Clinical Research
Fast-moving information is key if mid-sized CROs are to keep up with their larger competitors, and the best way to do this is with an integrated clinical trial management system
|
|
|
|
A Golden Opportunity… But Not a Silver Bullet
Barry Balfe at ICON
Pharmaceutical companies are increasing their functional service partnership expenditure at a rapid rate, but key considerations in selecting and executing the FSP model are being overlooked
|
|
|
|
The New York Hot Zone
EPC sits down with Dr Christina Brennan at Northwell Health to discuss the running of COVID-19 treatment trials during the current pandemic
|
|
|
|
|
|
Data Sharing: Safely Facilitated Through Shared Responsibility
Oli Cram at Elsevier
Not everyone is willing to share, so how can researchers, institutions, and drug manufacturers meet their ethical obligations, without jeopardising their commitments to compliance, copyright, and privacy protection?
|
|
|
|
Outcome Solutions in Medical Research
Dr Bill Byrom, Dr Denis Curtin, Dr David Daniel, Dr Alan Kott, and Dr Gary Sachs at Signant Health
By using a hypothetical protocol in CNS clinical research, it is possible to illustrate new approaches to common real world study challenges that research teams face
|
|
|
|
The ‘New Normal’ Requires Modernised Operations
Life science companies that adopt clinical trial technologies to meet immediate COVID-19 challenges are turning industry disruption into clinical trial management transformation
|
|
|
|
The Home-Working Data Manager
Jonathan Hart-Smith at CK Group
Times are changing, as are the working habits of data managers. With uncertainty abound, the question on everyone’s minds is – what happens next?
|
|
|
|
The Importance of CDMS in the Clinical Study Process
Rohit Jain and Rebecca Lorenzo at Axtria, Inc.
Implementing and executing a clinical data management system provides a foundation for error-free data collection to meet rapidly advancing technological and business needs with improved accuracy and efficiency
|
|
|
|
|
|
